GERN Stock Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.67|
|52 Week High||US$1.74|
|52 Week Low||US$0.99|
|1 Month Change||21.01%|
|3 Month Change||7.05%|
|1 Year Change||14.38%|
|3 Year Change||20.14%|
|5 Year Change||-40.57%|
|Change since IPO||-78.45%|
Recent News & Updates
Geron: TLR Is 10 Months Away
Top line results or TLR from the IMerge phase 3 trial will be out by January 2023. This is a confirmatory trial that may lead to an NDA, if successful. The CEO says he can't wait. Guess what, neither can we.
|GERN||US Biotechs||US Market|
Return vs Industry: GERN exceeded the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: GERN exceeded the US Market which returned -21.2% over the past year.
|GERN Average Weekly Movement||12.1%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: GERN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: GERN's weekly volatility (12%) has been stable over the past year.
About the Company
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Fundamentals Summary
|GERN fundamental statistics|
Is GERN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GERN income statement (TTM)|
|Cost of Revenue||US$3.60m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.31|
|Net Profit Margin||-8,584.92%|
How did GERN perform over the long term?See historical performance and comparison
Is GERN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GERN?
Other financial metrics that can be useful for relative valuation.
|What is GERN's n/a Ratio?|
Price to Book Ratio vs Peers
How does GERN's PB Ratio compare to its peers?
|GERN PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
CHRS Coherus BioSciences
SGMO Sangamo Therapeutics
VNDA Vanda Pharmaceuticals
Price-To-Book vs Peers: GERN is good value based on its Price-To-Book Ratio (6.5x) compared to the peer average (13.1x).
Price to Earnings Ratio vs Industry
How does GERN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: GERN is expensive based on its Price-To-Book Ratio (6.5x) compared to the US Biotechs industry average (1.5x)
Price to Book Ratio vs Fair Ratio
What is GERN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||6.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate GERN's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of GERN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GERN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GERN's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GERN's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Geron forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GERN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GERN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GERN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GERN's revenue (66.9% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: GERN's revenue (66.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GERN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Geron performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GERN is currently unprofitable.
Growing Profit Margin: GERN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GERN is unprofitable, and losses have increased over the past 5 years at a rate of 34.6% per year.
Accelerating Growth: Unable to compare GERN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GERN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: GERN has a negative Return on Equity (-121.44%), as it is currently unprofitable.
Discover strong past performing companies
How is Geron's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GERN's short term assets ($175.9M) exceed its short term liabilities ($46.6M).
Long Term Liabilities: GERN's short term assets ($175.9M) exceed its long term liabilities ($54.3M).
Debt to Equity History and Analysis
Debt Level: GERN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GERN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GERN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GERN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 31.7% each year.
Discover healthy companies
What is Geron current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GERN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GERN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GERN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GERN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GERN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chip Scarlett (71 yo)
Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and has been its President since January 5, 2012. Dr. Scarlett is C...
CEO Compensation Analysis
Compensation vs Market: Chip's total compensation ($USD2.06M) is below average for companies of similar size in the US market ($USD4.03M).
Compensation vs Earnings: Chip's compensation has increased whilst the company is unprofitable.
Experienced Management: GERN's management team is considered experienced (3.5 years average tenure).
Experienced Board: GERN's board of directors are seasoned and experienced ( 10.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.5%.
Geron Corporation's employee growth, exchange listings and data sources
- Name: Geron Corporation
- Ticker: GERN
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$630.337m
- Shares outstanding: 377.45m
- Website: https://www.geron.com
Number of Employees
- Geron Corporation
- 919 East Hillsdale Boulevard
- Suite 250
- Foster City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/04 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.